DDInter504 DDInter1676
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Desipramine {u} (Compound) resembles {v} (Compound) Aprindine
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Desipramine {u} (Compound) binds {v} (Gene) SLC22A2
Desipramine {u} (Compound) upregulates {v} (Gene) ALDOC
Desipramine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Desipramine {u} (Compound) downregulates {v} (Gene) HAT1
Desipramine {u} (Compound) causes {v} (Side Effect) Disturbance in sexual arousal
Desipramine (Compound) resembles Aprindine (Compound)
Desipramine (Compound) resembles Protriptyline (Compound)
Desipramine (Compound) binds SLC22A2 (Gene)
Desipramine (Compound) upregulates ALDOC (Gene)
Desipramine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Desipramine (Compound) downregulates HAT1 (Gene)
Desipramine (Compound) causes Disturbance in sexual arousal (Side Effect)